Who Paid My Doc
Luma Ghalib
Endocrinology, Diabetes & Metabolism Columbus, OH
NPI 1780658575 CMS profile 755935
543 Taylor Ave, Columbus, OH 43203
General payments
$0
Research payments
$0
Ownership & investment interest
$0
The CMS Open Payments record contains no reported payments to Luma Ghalib of Columbus, OH.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
Prescribing to Medicare patients
Part D · data year 2024 · 19 drugsPart D claims
1,174
Drug cost
$625,455
Branded share of claims
17.2%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Mycapssa Octreotide Acetate | Brand | 24 | $165,575 | |
| Isturisa Osilodrostat Phosphate | Brand | 11 | $162,465 | |
| Somavert Pegvisomant | Brand | 14 | $154,524 | |
| Trulicity Dulaglutide | Brand | 42 | $48,443 | |
| Jardiance Empagliflozin | Brand | 43 | $41,747 | |
| Testosterone | Generic | 100 | $15,935 | |
| Hydrocortisone | Generic | 179 | $7,761 | |
| Cabergoline | Generic | 78 | $6,760 | |
| Desmopressin Acetate | Generic | 71 | $6,084 | |
| Tradjenta Linagliptin | Brand | 11 | $5,320 |
The 10 drugs with the highest cost, of 19 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 6,527 Part D prescribers listed as Endocrinology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 14 billing codesPaid by Medicare
$23,272
Medicare patients
204
Services billed
324
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 49% | |
| Diabetes | 45% | |
| Depression | 40% | |
| Chronic kidney disease | 38% | |
| Ischemic heart disease | 30% | |
| Cancer | 27% | |
| Heart failure | 24% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Other Endocrinology, Diabetes & Metabolism in Ohio
Elena Christofides
Endocrinology, Diabetes & Metabolism · Columbus, OH
Kevin Pantalone
Endocrinology, Diabetes & Metabolism · Cleveland, OH
John Paes
Endocrinology, Diabetes & Metabolism · Westerville, OH
Samuel Anderson
Endocrinology, Diabetes & Metabolism · Columbus, OH
Bhaskar Gundabolu
Endocrinology, Diabetes & Metabolism · Toledo, OH
Nelson Watts
Endocrinology, Diabetes & Metabolism · Cincinnati, OH
Related records
Endocrinology, Diabetes & Metabolism in Ohio
Practitioners in the same specialty and state, ranked by reported value.
All Endocrinology, Diabetes & Metabolism
Everyone recorded under this specialty, nationwide.
Doctors in Ohio
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.